1. Home
  2. HUMAW
  3. HUMAW News

Latest Humacyte Inc. Warrant (HUMAW) News on October 31, 2025

Humacyte, Inc. (HUMA) Surpasses Market Returns: Some Facts Worth Knowing
HUMAW

Zacks

7 days ago

Humacyte, Inc. (HUMA) Surpasses Market Returns: Some Facts Worth Knowing

Humacyte, Inc. (HUMA) Laps the Stock Market: Here's Why
HUMAW

Zacks

14 days ago

Humacyte, Inc. (HUMA) Laps the Stock Market: Here's Why

Humacyte (HUMA): Valuation in Focus After Promising Ukraine Trauma Results
HUMAW

Simply Wall St.

15 days ago

Humacyte (HUMA): Valuation in Focus After Promising Ukraine Trauma Results

Humacyte, Inc. (HUMA) Advances While Market Declines: Some Information for Investors
HUMAW

Zacks

17 days ago

Humacyte, Inc. (HUMA) Advances While Market Declines: Some Information for Investors

HUMAW

ACCESS Newswire

17 days ago

D. Boral Capital Acted as Exclusive Placement Agent to Humacyte (Nasdaq: HUMA) in Connection with its $60,000,000 Registered Direct Offering

Humacyte (HUMA) Is Down 25.7% After Reporting Strong Symvess Trauma Results and Completing $60M Equity Raise
HUMAW

Simply Wall St.

19 days ago

Humacyte (HUMA) Is Down 25.7% After Reporting Strong Symvess Trauma Results and Completing $60M Equity Raise

Humacyte, Inc. (HUMA) Declines More Than Market: Some Information for Investors
HUMAW

Zacks

24 days ago

Humacyte, Inc. (HUMA) Declines More Than Market: Some Information for Investors

HUMAW

MT Newswires

24 days ago

Top Midday Decliners

Humacyte Gains 43%, Insider Trades Reap Benefit
HUMAW

Simply Wall St.

24 days ago

Humacyte Gains 43%, Insider Trades Reap Benefit

HUMAW

MT Newswires

24 days ago

Humacyte Prices $60 Million Oversubscribed Registered Direct Offering; Shares Tumble

Humacyte Announces Pricing of $60.0 Million Oversubscribed Registered Direct Offering
HUMAW

GlobeNewswire

24 days ago

Humacyte Announces Pricing of $60.0 Million Oversubscribed Registered Direct Offering

Humacyte, Inc. (HUMA) Stock Moves -1.79%: What You Should Know
HUMAW

Zacks

4 months ago

Humacyte, Inc. (HUMA) Stock Moves -1.79%: What You Should Know

Owning 40% shares,institutional owners seem interested in Humacyte, Inc. (NASDAQ:HUMA),
HUMAW

Simply Wall St.

4 months ago

Owning 40% shares,institutional owners seem interested in Humacyte, Inc. (NASDAQ:HUMA),

Humacyte, Inc. (HUMA) Gains As Market Dips: What You Should Know
HUMAW

Zacks

4 months ago

Humacyte, Inc. (HUMA) Gains As Market Dips: What You Should Know

Results from Humacyte’s V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting
HUMAW

GlobeNewswire

5 months ago

Results from Humacyte’s V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting

Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3
HUMAW

GlobeNewswire

5 months ago

Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3

Exploring 3 High Growth Tech Stocks In The US Market
HUMAW

Simply Wall St.

5 months ago

Exploring 3 High Growth Tech Stocks In The US Market

Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq
HUMAW

GlobeNewswire

5 months ago

Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq

Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update
HUMAW

GlobeNewswire

6 months ago

Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update

Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025
HUMAW

GlobeNewswire

6 months ago

Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025

Humacyte Insiders Placed Bullish Bets Worth US$949.4k
HUMAW

Simply Wall St.

6 months ago

Humacyte Insiders Placed Bullish Bets Worth US$949.4k

Lululemon reports Q4 beat, CoreWeave IPO priced at $40: Morning Buzz
HUMAW

TipRanks

7 months ago

Lululemon reports Q4 beat, CoreWeave IPO priced at $40: Morning Buzz

Humacyte price target lowered to $8 from $10 at BTIG
HUMAW

TipRanks

7 months ago

Humacyte price target lowered to $8 from $10 at BTIG

Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update
HUMAW

GlobeNewswire

7 months ago

Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025
HUMAW

GlobeNewswire

7 months ago

Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock
HUMAW

GlobeNewswire

7 months ago

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

Humacyte, Inc. Announces Proposed Public Offering of Common Stock
HUMAW

GlobeNewswire

7 months ago

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics
HUMAW

GlobeNewswire

8 months ago

Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics

Trestle Bio Announces Research Collaboration with Humacyte
HUMAW

Business Wire

8 months ago

Trestle Bio Announces Research Collaboration with Humacyte

Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025
HUMAW

GlobeNewswire

8 months ago

Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025

Humacyte to Present at the TD Cowen 45th Annual Health Care Conference
HUMAW

GlobeNewswire

8 months ago

Humacyte to Present at the TD Cowen 45th Annual Health Care Conference

Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered Tissues
HUMAW

GlobeNewswire

8 months ago

Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered Tissues

Humacyte Announces Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma
HUMAW

GlobeNewswire

8 months ago

Humacyte Announces Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma

When Will Humacyte, Inc. (NASDAQ:HUMA) Breakeven?
HUMAW

Simply Wall St.

8 months ago

When Will Humacyte, Inc. (NASDAQ:HUMA) Breakeven?

Humacyte and Pluristyx Announce Gene Editing Partnership to Support BioVascular Pancreas (BVP™) Development Using iPSCs
HUMAW

GlobeNewswire

9 months ago

Humacyte and Pluristyx Announce Gene Editing Partnership to Support BioVascular Pancreas (BVP™) Development Using iPSCs

Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting
HUMAW

GlobeNewswire

9 months ago

Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting

Humacyte Provides Update on Commercial Launch and Pricing of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma
HUMAW

GlobeNewswire

10 months ago

Humacyte Provides Update on Commercial Launch and Pricing of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma

Humacyte price target raised to $17 from $15 at Benchmark
HUMAW

TipRanks

10 months ago

Humacyte price target raised to $17 from $15 at Benchmark

High Growth Tech Stocks to Watch in December 2024
HUMAW

Simply Wall St.

10 months ago

High Growth Tech Stocks to Watch in December 2024

Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma
HUMAW

GlobeNewswire

10 months ago

Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma

Individual investors who have a significant stake must be disappointed along with institutions after Humacyte, Inc.'s (NASDAQ:HUMA) market cap dropped by US$60m
HUMAW

Simply Wall St.

10 months ago

Individual investors who have a significant stake must be disappointed along with institutions after Humacyte, Inc.'s (NASDAQ:HUMA) market cap dropped by US$60m

Humacyte to Present at the Piper Sandler 36th Annual Healthcare Conference
HUMAW

GlobeNewswire

a year ago

Humacyte to Present at the Piper Sandler 36th Annual Healthcare Conference

Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH)
HUMAW

GlobeNewswire

a year ago

Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH)

Insider Buyers At Humacyte Likely Disappointed With 17% Slide
HUMAW

Simply Wall St.

a year ago

Insider Buyers At Humacyte Likely Disappointed With 17% Slide

Humacyte Clinical Results Highlighting Benefit of the ATEV™ in the Repair of Civilian and Military Arterial Injuries Published in JAMA Surgery
HUMAW

GlobeNewswire

a year ago

Humacyte Clinical Results Highlighting Benefit of the ATEV™ in the Repair of Civilian and Military Arterial Injuries Published in JAMA Surgery

Humacyte Presents Preclinical Results of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting at American Heart Association’s Scientific Sessions 2024
HUMAW

GlobeNewswire

a year ago

Humacyte Presents Preclinical Results of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting at American Heart Association’s Scientific Sessions 2024

Humacyte Announces Pricing of $15.0 Million Registered Direct Offering
HUMAW

GlobeNewswire

a year ago

Humacyte Announces Pricing of $15.0 Million Registered Direct Offering

Humacyte Third Quarter 2024 Financial Results and Business Update
HUMAW

GlobeNewswire

a year ago

Humacyte Third Quarter 2024 Financial Results and Business Update

Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 8, 2024
HUMAW

GlobeNewswire

a year ago

Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 8, 2024

Humacyte Announces Presentation of Positive Results from V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024
HUMAW

GlobeNewswire

a year ago

Humacyte Announces Presentation of Positive Results from V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024

High Growth Tech Stocks to Watch in October 2024
HUMAW

Simply Wall St.

a year ago

High Growth Tech Stocks to Watch in October 2024

Humacyte to Host Virtual KOL Event on the Use of Acellular Tissue Engineered Vessel (ATEV™) for AV Access in Hemodialysis on October 31, 2024
HUMAW

GlobeNewswire

a year ago

Humacyte to Host Virtual KOL Event on the Use of Acellular Tissue Engineered Vessel (ATEV™) for AV Access in Hemodialysis on October 31, 2024

‘It’s Spare Parts for People’: Blood Vessels Grown in a Lab
HUMAW

The Wall Street Journal

a year ago

‘It’s Spare Parts for People’: Blood Vessels Grown in a Lab

Humacyte Late-Breaking Abstract Accepted for Oral Presentation on V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024
HUMAW

GlobeNewswire

a year ago

Humacyte Late-Breaking Abstract Accepted for Oral Presentation on V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024

Humacyte Launches $30M Stock and Warrants Offering
HUMAW

TipRanks

a year ago

Humacyte Launches $30M Stock and Warrants Offering

Humacyte Announces Pricing of $30.0 Million Registered Direct Offering
HUMAW

GlobeNewswire

a year ago

Humacyte Announces Pricing of $30.0 Million Registered Direct Offering

Humacyte to Host Virtual KOL Event to Discuss Case Studies on the Use of Acellular Tissue Engineered Vessel (ATEV™) in Vascular Trauma Treatment on September 30, 2024
HUMAW

GlobeNewswire

a year ago

Humacyte to Host Virtual KOL Event to Discuss Case Studies on the Use of Acellular Tissue Engineered Vessel (ATEV™) in Vascular Trauma Treatment on September 30, 2024

Exploring Three High Growth Tech Stocks in the United States
HUMAW

Simply Wall St.

a year ago

Exploring Three High Growth Tech Stocks in the United States

Humacyte Announces Allowance of U.S. Patent Covering BioVascular Pancreas (BVP™)
HUMAW

GlobeNewswire

a year ago

Humacyte Announces Allowance of U.S. Patent Covering BioVascular Pancreas (BVP™)

Humacyte to Participate at Upcoming Investor Conferences in September
HUMAW

GlobeNewswire

a year ago

Humacyte to Participate at Upcoming Investor Conferences in September

Humacyte Presents Positive Long-Term Results of ATEV™ in Treatment of Vascular Trauma in Military Setting from Ukraine Humanitarian Program
HUMAW

GlobeNewswire

a year ago

Humacyte Presents Positive Long-Term Results of ATEV™ in Treatment of Vascular Trauma in Military Setting from Ukraine Humanitarian Program

Humacyte Second Quarter 2024 Financial Results and Business Update
HUMAW

GlobeNewswire

a year ago

Humacyte Second Quarter 2024 Financial Results and Business Update

Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 13, 2024
HUMAW

GlobeNewswire

a year ago

Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 13, 2024

Humacyte Announces FDA Communication of Additional Time Required to Complete Review of acellular tissue engineered vessel (ATEV™) BLA for the Treatment of Vascular Trauma
HUMAW

GlobeNewswire

a year ago

Humacyte Announces FDA Communication of Additional Time Required to Complete Review of acellular tissue engineered vessel (ATEV™) BLA for the Treatment of Vascular Trauma

Companies Like Humacyte (NASDAQ:HUMA) Are In A Position To Invest In Growth
HUMAW

Simply Wall St.

a year ago

Companies Like Humacyte (NASDAQ:HUMA) Are In A Position To Invest In Growth

Humacyte Acellular Tissue Engineered Vessel (ATEV™) Meets Primary Endpoints in V007 Phase 3 Clinical Trial in Arteriovenous Access for Hemodialysis
HUMAW

GlobeNewswire

a year ago

Humacyte Acellular Tissue Engineered Vessel (ATEV™) Meets Primary Endpoints in V007 Phase 3 Clinical Trial in Arteriovenous Access for Hemodialysis

Humacyte Board of Directors Strengthened with Addition of John P. Bamforth and Keith Anthony Jones
HUMAW

GlobeNewswire

a year ago

Humacyte Board of Directors Strengthened with Addition of John P. Bamforth and Keith Anthony Jones

Pluristyx Announces License Agreement with Humacyte to Develop BioVascular Pancreas using iPSCs
HUMAW

Business Wire

a year ago

Pluristyx Announces License Agreement with Humacyte to Develop BioVascular Pancreas using iPSCs

While institutions own 20% of Humacyte, Inc. (NASDAQ:HUMA), individual investors are its largest shareholders with 50% ownership
HUMAW

Simply Wall St.

a year ago

While institutions own 20% of Humacyte, Inc. (NASDAQ:HUMA), individual investors are its largest shareholders with 50% ownership

Humacyte Acellular Tissue Engineered Vessel (ATEV™) Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for Patients with Advanced Peripheral Artery Disease (PAD)
HUMAW

GlobeNewswire

a year ago

Humacyte Acellular Tissue Engineered Vessel (ATEV™) Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for Patients with Advanced Peripheral Artery Disease (PAD)

Humacyte Presents Positive Preclinical Data For Its BioVascular Pancreas (BVP™) Program
HUMAW

GlobeNewswire

a year ago

Humacyte Presents Positive Preclinical Data For Its BioVascular Pancreas (BVP™) Program

Centers for Medicare & Medicaid Services (CMS) Issues ICD-10-PCS Codes for Humacyte’s Human Acellular Vessel™ (HAV™)
HUMAW

GlobeNewswire

a year ago

Centers for Medicare & Medicaid Services (CMS) Issues ICD-10-PCS Codes for Humacyte’s Human Acellular Vessel™ (HAV™)

HUMAW

Business Wire

a year ago

Net Asset Value(s)

Dstny honored with 'Employee Wellbeing Award'
HUMAW

PR Newswire

a year ago

Dstny honored with 'Employee Wellbeing Award'

Huawei Reveals How to Reach Premium Asian Tourists at Digital Tourist 2024
HUMAW

PR Newswire

a year ago

Huawei Reveals How to Reach Premium Asian Tourists at Digital Tourist 2024

Amber Therapeutics Closes $100 Million Series A Financing to Advance Breakthrough Amber-UI Neuromodulation Therapy for Mixed Urinary Incontinence towards US FDA Approval
HUMAW

GlobeNewswire

a year ago

Amber Therapeutics Closes $100 Million Series A Financing to Advance Breakthrough Amber-UI Neuromodulation Therapy for Mixed Urinary Incontinence towards US FDA Approval

Entrust Enables Governments to Transform Citizen Interactions with Digital Identities
HUMAW

Business Wire

a year ago

Entrust Enables Governments to Transform Citizen Interactions with Digital Identities

Global Automotive HMI Market Size To Worth USD 75.3 Billion By 2033 l CAGR 12.36%
HUMAW

GlobeNewswire

a year ago

Global Automotive HMI Market Size To Worth USD 75.3 Billion By 2033 l CAGR 12.36%

RETRANSMISSION: First Hydrogen's FCEV Completes Successful Trial with Amazon
HUMAW

Newsfile

a year ago

RETRANSMISSION: First Hydrogen's FCEV Completes Successful Trial with Amazon

MOURI Tech Announces Acquisition of Vertisystem, Enhancing IT Service Offerings and Extending Market Presence
HUMAW

Business Wire

a year ago

MOURI Tech Announces Acquisition of Vertisystem, Enhancing IT Service Offerings and Extending Market Presence

HUMAW

Journal-News, Hamilton, Ohio

a year ago

Retiring ODW executive to be first inductee in Hamilton Business Hall of Fame

Once-in-a-Generation Investment Opportunity: Why You Should Buy Carnival Stock Now
HUMAW

Motley Fool

a year ago

Once-in-a-Generation Investment Opportunity: Why You Should Buy Carnival Stock Now

Cat-sitting startup Meowtel clawed its way to profitability despite trouble raising from dog-focused VCs
HUMAW

TechCrunch

a year ago

Cat-sitting startup Meowtel clawed its way to profitability despite trouble raising from dog-focused VCs

Italian energy company targets Britain for fleet of 20 mini-nukes
HUMAW

The Telegraph

a year ago

Italian energy company targets Britain for fleet of 20 mini-nukes

It Might Not Be A Great Idea To Buy StepStone Group LP (NASDAQ:STEP) For Its Next Dividend
HUMAW

Simply Wall St.

a year ago

It Might Not Be A Great Idea To Buy StepStone Group LP (NASDAQ:STEP) For Its Next Dividend

Saudis Said to Hand About 60% of Aramco Offer to Foreigners
HUMAW

Bloomberg

a year ago

Saudis Said to Hand About 60% of Aramco Offer to Foreigners

Is Now The Time To Put Planet Fitness (NYSE:PLNT) On Your Watchlist?
HUMAW

Simply Wall St.

a year ago

Is Now The Time To Put Planet Fitness (NYSE:PLNT) On Your Watchlist?

Don't Buy Banc of California, Inc. (NYSE:BANC) For Its Next Dividend Without Doing These Checks
HUMAW

Simply Wall St.

a year ago

Don't Buy Banc of California, Inc. (NYSE:BANC) For Its Next Dividend Without Doing These Checks

This Is Why Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation Looks Appropriate
HUMAW

Simply Wall St.

a year ago

This Is Why Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation Looks Appropriate

Insider Sale: COO Heather Prichard Divests All Shares in Humacyte Inc (HUMA)
HUMAW

GuruFocus.com

a year ago

Insider Sale: COO Heather Prichard Divests All Shares in Humacyte Inc (HUMA)

Humacyte to Present at the Jefferies Global Healthcare Conference
HUMAW

GlobeNewswire

a year ago

Humacyte to Present at the Jefferies Global Healthcare Conference

This Humacyte Insider Increased Their Holding By 91% Last Year
HUMAW

Simply Wall St.

a year ago

This Humacyte Insider Increased Their Holding By 91% Last Year

Humacyte to Participate at Upcoming Investor Conferences in May
HUMAW

GlobeNewswire

a year ago

Humacyte to Participate at Upcoming Investor Conferences in May

HUMAW

GuruFocus.com

a year ago

Humacyte Inc (HUMA) Q1 2024 Earnings: Aligns with Analyst Projections Amid Strategic Advances

Humacyte First Quarter 2024 Financial Results and Business Update
HUMAW

GlobeNewswire

a year ago

Humacyte First Quarter 2024 Financial Results and Business Update

Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 10, 2024
HUMAW

GlobeNewswire

a year ago

Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 10, 2024

Humacyte to Host Virtual KOL Event “Hemodialysis Access: A Crossroads of Care,” on March 28, 2024
HUMAW

GlobeNewswire

2 years ago

Humacyte to Host Virtual KOL Event “Hemodialysis Access: A Crossroads of Care,” on March 28, 2024

Humacyte, Inc. (NASDAQ:HUMA) Q4 2023 Earnings Call Transcript
HUMAW

Insider Monkey

2 years ago

Humacyte, Inc. (NASDAQ:HUMA) Q4 2023 Earnings Call Transcript

Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update
HUMAW

GlobeNewswire

2 years ago

Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update

Humacyte to Present 2023 Fourth Quarter and Year-End Financial Results and Provide Corporate Update on March 22, 2024
HUMAW

GlobeNewswire

2 years ago

Humacyte to Present 2023 Fourth Quarter and Year-End Financial Results and Provide Corporate Update on March 22, 2024

Share on Social Networks: